Zoledronic Acid Reduces the Need for Radiation to Bone in Patients with Breast or Prostate Cancer Metastatic to Bone: A Survival-Adjusted Cumulative Incidence Analysis

PP Major,RJ Cook,BL Chen,M Zheng

DOI: https://doi.org/10.1200/jco.2004.22.90140.8058

IF: 45.3

2004-01-01

Journal of Clinical Oncology

Abstract:8058 Background: Bone metastases are common in patients with breast or prostate cancer and cause significant pain and skeletal morbidity. The need for radiation to bone to treat pain or prevent a fracture is a significant clinical event associated with disease progression and quality-of-life decline. Therefore, radiation to bone was included in the composite endpoints describing skeletal morbidity in recent clinical trials of zoledronic acid. Herein, a statistically robust nonparametric method was used to measure the cumulative burden of radiation to bone over the entire course of follow-up to evaluate the benefit of 4-mg zoledronic acid in patients with breast or prostate cancer enrolled in 2 large, randomized, phase III trials. We have previously reported by this method that zoledronic acid significantly reduces the overall cumulative incidence of skeletal complications compared with placebo or pamidronate (Pam) in these patient populations. Methods: These trials were GCP-compliant, and patients gave written informed consent. Patients received 4 mg zoledronic acid via 15-minute infusion every 3–4 weeks for 2 years. Comparators were 90 mg Pam via 2-hour infusion (breast cancer) or placebo (prostate cancer). Survival-adjusted multiple event analysis was performed via the methods of Cook et al. (Stat Med 1997;16;911–924) and Ghosh and Lin (Biometrics 2000;56:554–562). Results: In patients with breast cancer (n = 766), 4 mg zoledronic acid was superior to 90 mg Pam and significantly reduced the cumulative mean number of administrations of radiation to bone by 35.4% at 25 months (P = .003), adding to the benefit achieved with Pam. Similarly, in patients with prostate cancer, 4 mg zoledronic acid significantly reduced the cumulative mean number of administrations of radiation to bone by 33.2% compared with placebo at 24 months (P = .034). Conclusion: This new, robust method provides a simple graphic representation of the cumulative need for radiation therapy and reveals the significant reduction in need for radiation therapy achieved with zoledronic acid in breast or prostate cancer patients. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Novartis Pharmaceuticals Novartis (US)